688029.SHG Micro Tech Nanjing Co Ltd
- Market cap
- CNY 16.5B
- P/E
- 34.4x
- P/B
- 3.78x
- ROE
- 13.3%
- Dividend yield
- 1.71%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 688029.SHG undervalued?
Graham number688029.SHG trades 140.4% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Micro Tech Nanjing Co Ltd fundamental analysis
No fundamental analysis for Micro Tech Nanjing Co Ltd yet.
Micro Tech Nanjing Co Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Micro Tech Nanjing Co Ltd
Micro-Tech (Nanjing) Co.,Ltd, together with its subsidiaries, engages in the research, development, manufacturing, and sale of minimally invasive medical devices in China and internationally. The company offers digestive endoscopy products, including ESD, such as electric flushing device, harmony/GT gold clip, gold/titanium knife, pull clamp, three-arm clap, hemostatic titanium forceps, injection needle, vascular clamp, spray pipe, electric oil, and indigo carmine muscosal s…
Full company profileMicro Tech Nanjing Co Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Micro Tech Nanjing Co Ltd annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 414M | 641M | 922M | 1.31B | 1.33B | 1.95B | 1.98B | 2.41B | 2.76B | 3.19B | 3.35B |
| Gross Profit | 234M | 381M | 583M | 856M | 862M | 1.23B | 1.18B | 1.52B | 1.81B | 3.19B | 2.15B |
| Operating Income | -14.4M | 132M | 229M | 352M | 282M | 367M | 364M | 555M | 659M | 692M | 801M |
| EBITDA | 2.51M | 143M | 257M | 384M | 332M | 419M | 427M | 633M | 732M | 754M | 702M |
| Net Income | -36.5M | 101M | 193M | 304M | 261M | 325M | 331M | 486M | 553M | 570M | 555M |
| EPS | -0.27 | 0.72 | 1.38 | 1.90 | 1.40 | 1.72 | 1.75 | 2.59 | 2.95 | 3.05 | 2.95 |
| Balance Sheet | |||||||||||
| Total Assets | 541M | 718M | 969M | 2.88B | 3.11B | 3.63B | 3.89B | 4.39B | 4.78B | 5.46B | 5.52B |
| Total Liabilities | 182M | 252M | 349M | 347M | 442M | 641M | 620M | 723M | 880M | -4.24B | 1.13B |
| Shareholders' Equity | 335M | 436M | 580M | 2.48B | 2.61B | 2.94B | 3.23B | 3.61B | 3.83B | 4.24B | 4.18B |
| Cash & Short-term Investments | 118M | 173M | 341M | 2.00B | 2.03B | 2.00B | 1.89B | 2.31B | 2.29B | 2.21B | 1.64B |
| Total Debt | 70.0M | 96.1M | 96.2M | - | 22.7M | 14.4M | 11.9M | 35.9M | 89.0M | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 80.0M | 140M | 192M | 252M | 231M | 173M | 250M | 546M | 613M | 688M | - |
| Capital Expenditure | 35.8M | 53.4M | 48.8M | 53.5M | 162M | 165M | 213M | 256M | 270M | 255M | 178M |
| Free Cash Flow | 44.1M | 87.0M | 144M | 199M | 69.2M | 8.14M | 36.8M | 289M | 400M | 433M | 447M |
| Ratios | |||||||||||
| ROE | -10.9% | 23.2% | 33.2% | 12.3% | 10.0% | 11.0% | 10.3% | 13.5% | 14.5% | 13.4% | 13.3% |
| ROA | -6.7% | 14.1% | 19.9% | 10.6% | 8.4% | 8.9% | 8.5% | 11.1% | 11.6% | 10.4% | 10.1% |
| Net Profit Margin | -8.8% | 15.8% | 20.9% | 23.2% | 19.7% | 16.7% | 16.7% | 20.2% | 20.1% | 17.9% | 16.5% |
| Debt to Equity | 0.21x | 0.22x | 0.17x | - | 0.01x | 0.00x | 0.00x | 0.01x | 0.02x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Micro Tech Nanjing Co Ltd dividends
- Dividend yield
- 1.71%
- Forward dividend
- 1.50 CNY
- Payout ratio
- 49.5%
- Ex-dividend date
- Oct 23, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 282M | 1.51 | 49.5% |
| 2024 | CNY 281M | 1.50 | 50.8% |
| 2023 | CNY 105M | 0.56 | 21.5% |
| 2022 | CNY 100M | 0.53 | 30.3% |
| 2021 | CNY 80.0M | 0.42 | 24.6% |
| 2020 | CNY 133M | 0.71 | 51.1% |
| 2019 | CNY 52.2M | 0.33 | 17.2% |
| 2018 | CNY 4.23M | 0.03 | 2.2% |
| 2017 | CNY 3.83M | 0.03 | 3.8% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1.4:1 on Jun 10, 2022.
Who owns Micro Tech Nanjing Co Ltd
- Insiders 48.93%
- Institutions 17.63%
- Public & others 33.44%
- Shares outstanding 188M
- Free float 84.5M
Micro Tech Nanjing Co Ltd company profile
- Company name
- Micro Tech Nanjing Co Ltd
- Ticker
- 688029.SHG
- ISIN
- CNE100003MG1
- Exchange
- Shanghai Stock Exchange
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 2,433
- Fiscal year end
- December
- Address
- No. 10, Gaoke Third Road, Nanjing, China, 210032
- Phone
- 86 40 0025 3000
- Website
- micro-tech.com.cn
About Micro Tech Nanjing Co Ltd
Micro-Tech (Nanjing) Co.,Ltd, together with its subsidiaries, engages in the research, development, manufacturing, and sale of minimally invasive medical devices in China and internationally. The company offers digestive endoscopy products, including ESD, such as electric flushing device, harmony/GT gold clip, gold/titanium knife, pull clamp, three-arm clap, hemostatic titanium forceps, injection needle, vascular clamp, spray pipe, electric oil, and indigo carmine muscosal staining agent; and ERCP comprising biliary duct drainage tube, nasobiliary drainage catheter, stone removal balloon, stone retrieval basket, level 3 balloon dilation catheter, guide wire, ruyi knife, and eyemax insights. It also provides hemostasis, which includes bandage and star king clip; dilation and biopsy, such as covered biliary stent, biliary stent, intestinal stent kit with biopsy access, intestinal stent, covered intestinal stent, segmented esophageal stent system, and covered esophageal stent kit; EUS comprising ultrasonic water bag and ultrasonic needle; cell brush; and net ring toss, cleaning brush, mouth pad, and foreign body forceps. In addition, the company offers interventional radiology and surgical devices. The company was founded in 2000 and is headquartered in Nanjing, China.
Micro Tech Nanjing Co Ltd management
10- Mr. Derong LengPresident & Director · born 1963
- Mr. Changqing LiExecutive President & Director · born 1971
- Mr. Chenwei RuiSenior VP, CFO & Chief Accountant · born 1979
- Mr. Jiefeng XiChief Scientist and Senior Director of R&D · born 1982
- Mr. Bo ZhangSenior VP & Director · born 1970
- Mr. Jian Yu WeiSenior Chief Engineer · born 1980
- Mr. Daniel KuhnSenior Vice President · born 1960
- Mr. Feng ZhangSenior Vice President · born 1973
- Mr. Gong XingliangVP & Secretary of the Board · born 1973
- Ms. Ning LiDirector of Quality & Regulatory Affairs · born 1981